SER
Serina Therapeutics, Inc.
$1.84
+1.66%
$27.6M
No data for this timeframe.
Vol
Market Cap$27.6M
Cap SizeNano Cap
Inst. Holders9 funds
Inst. Value$624.0K
Inst. Activity1 buys / 0 sells
Insider Activity3B / 3S
Insider Net $-$78.6K
Reddit Sentiment67° Warm
SEC Reports5
Press Releases1
Recent Activity
Jun 4, 2026
SEC
The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June 3, 2026. This shelf
EFFECT — Impact 7/10
May 26, 2026
SEC
Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, representing ~0.13% o
CLUSTER — Impact 5/10
May 26, 2026
SEC
Two Serina directors made small open-market purchases totaling ~$38K in the 7-day window ending May 22, 2026. These trad
CLUSTER — Impact 5/10
May 26, 2026
Insider
LEDGER STEVEN A was granted 10,100 shares
Chief Executive Officer @ $1.93 ($19.5K)
May 22, 2026
Insider
WILSON KAREN J bought 10,000 shares
Director @ $1.93 ($19.3K)
May 21, 2026
Insider
Tenjarla Srini was granted 85,558 shares
SVP, CMC & Formulation
Inst.
BlackRock, Inc. — DOUBLED
58,264 shares ($113.0K)
Inst.
BlackRock, Inc. — ADD
17,249 shares ($33.0K)
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$11.00 (Aug 2025)
Current $1.84
Low $11.00
Median $11.00
High $11.00
1 analysts
$11.00
$11.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 28, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 14, 2025 | HC Wainwright & Co. | INITIATE | Buy |
| Mar 11, 2025 | Jones Trading | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.35 ▲ +23.1% | $-0.35 — $-0.35 | 47% YoY | 1 |
| Next Q | $-0.35 ▲ +23.9% | $-0.35 — $-0.35 | 32% YoY | 1 |
| Current FY | $-1.41 ▲ +21.9% | $-1.41 — $-1.41 | 1 | |
| Next FY | $-1.05 ▲ +25.0% | $-1.05 — $-1.05 | 26% YoY | 1 |
Latest Reports
BEARISH
EFFECT
7/10
The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June 3, 2026. This shelf
Jun 4, 2026
MIXED
CLUSTER
5/10
Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, representing ~0.13% o
May 26, 2026
MIXED
Press
7/10
Serina Therapeutics announced FDA clearance of its IND for SER-252, a POZ-apomorphine therapy for advanced Parkinson's d
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $308.7K | — |
| Waverly Advisors, LLC | $130.9K | DOUBLED |
| BlackRock, Inc. | $113.0K | DOUBLED |
| VANGUARD FIDUCIARY TRUST CO | $38.8K | — |
| STATE STREET CORP | $24.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | LEDGER STEVEN | A | $19.5K |
| May 22, 2026 | WILSON KAREN | BUY | $19.3K |
| May 21, 2026 | Tenjarla Srini | A | $0.00 |
| May 21, 2026 | WILSON KAREN | BUY | $17.7K |
| May 21, 2026 | CURHAN GREGORY | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
9 institutional holders with $624.0K total value (321,643 shares) as of 2026-Q1. Top holders: VANGUARD, Waverly, BlackRock,. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 159,136 | $308.7K | 49.5% | — |
| 2 | Waverly Advisors, LLC | 67,492 | $130.9K | 21.0% | DOUBLED +187.4% |
| 3 | BlackRock, Inc. | 58,264 | $113.0K | 18.1% | DOUBLED +237.8% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 20,009 | $38.8K | 6.2% | — |
| 5 | STATE STREET CORP | 12,758 | $24.8K | 4.0% | — |
| 6 | WELLS FARGO & COMPANY/MN | 3,606 | $7.0K | 1.1% | DOUBLED +180100.0% |
| 7 | Vanguard Global Advisers, LLC | 368 | $714.00 | 0.1% | — |
| 8 | MORGAN STANLEY | 8 | $16.00 | 0.0% | DOUBLED +100.0% |
| 9 | Rockefeller Capital Management L.P. | 2 | $4.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 17,249 | 58,264 | +237.8% | $113.0K | 2026-Q1 |
| BlackRock, Inc. | ADD | 13,122 | 17,249 | +31.5% | $33.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2 | 3,604 | +180100.0% | $6.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 215 | 3 | -98.6% | $6.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 1 | 3,466 | +346500.0% | $18.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 29 | 215 | +641.4% | $1.2K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 65,333 | 150,623 | +130.5% | $927.8K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 747 | 1 | -99.9% | $6.00 | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 3,809 | 747 | -80.4% | $4.2K | 2025-Q1 |
| VANGUARD GROUP INC | ADD | 44,500 | 62,073 | +39.5% | $311.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 1 | 3,809 | +380800.0% | $19.1K | 2024-Q4 |
| Waverly Advisors, LLC | DOUBLED | 23,485 | 67,492 | +187.4% | $451.5K | 2024-Q3 |
| VANGUARD GROUP INC | DOUBLED | 22,132 | 44,500 | +101.1% | $297.7K | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 4 | 8 | +100.0% | $54.00 | 2024-Q3 |
9 unique insiders with 20 transactions. Net insider value: -$78.6K ($57.1K bought, $135.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | LEDGER STEVEN A | Chief Executive Officer | AWARD | 10,100 | $1.93 | $19.5K |
| May 22, 2026 | WILSON KAREN J | Director | BUY | 10,000 | $1.93 | $19.3K |
| May 21, 2026 | Tenjarla Srini | SVP, CMC & Formulation | AWARD | 85,558 | — | — |
| May 21, 2026 | WILSON KAREN J | Director | BUY | 10,000 | $1.77 | $17.7K |
| May 21, 2026 | CURHAN GREGORY S | Chief Financial Officer | AWARD | 123,019 | — | — |
| May 21, 2026 | Moreadith Randall | Chief Scientific Officer | AWARD | 85,558 | — | — |
| May 21, 2026 | LEDGER STEVEN A | Chief Executive Officer | AWARD | 380,825 | — | — |
| May 19, 2026 | Marshall Richard Peter | Director | BUY | 12,183 | $1.65 | $20.1K |
| Mar 31, 2026 | Bailey Gregory | Director | AWARD | 59,667 | $1.94 | $115.8K |
| Mar 31, 2026 | Venkatesan Jay | Director | AWARD | 7,553 | $1.94 | $14.7K |
| Mar 23, 2026 | Moreadith Randall | Chief Scientific Officer | EXERCISE | 6,500 | $0.0600 | $390.00 |
| Mar 23, 2026 | Moreadith Randall | Chief Scientific Officer | SELL | 6,500 | $2.86 | $18.6K |
| Mar 19, 2026 | Moreadith Randall | Chief Scientific Officer | SELL | 39,000 | $2.50 | $97.5K |
| Mar 19, 2026 | Moreadith Randall | Chief Scientific Officer | EXERCISE | 39,000 | $0.0600 | $2.3K |
| Feb 3, 2026 | Moreadith Randall | Chief Scientific Officer | AWARD | 69,000 | — | — |
| Feb 3, 2026 | GILL SIMBA | Director | AWARD | 92,000 | — | — |
| Feb 3, 2026 | Tenjarla Srini | SVP, CMC & Formulation | AWARD | 69,000 | — | — |
| Feb 3, 2026 | LEDGER STEVEN A | Chief Executive Officer | AWARD | 230,100 | — | — |
| Feb 2, 2026 | Moreadith Randall | Chief Scientific Officer | EXERCISE | 6,500 | $0.0600 | $390.00 |
| Feb 2, 2026 | Moreadith Randall | Chief Scientific Officer | SELL | 6,500 | $3.03 | $19.7K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 1 neutral. Avg impact: 5.2/10.
BEARISH
EFFECT
7/10
The SEC declared effective Serina Therapeutics' S-3 shelf registration (File No. 333-296166) on June
Jun 4, 2026
MIXED
CLUSTER
5/10
Two directors at Serina Therapeutics made open-market purchases totaling $38K over a 3-day window, r
May 26, 2026
BEARISH
CLUSTER
5/10
Two Serina directors made small open-market purchases totaling ~$38K in the 7-day window ending May
May 26, 2026
BEARISH
S-3
7/10
Serina Therapeutics filed an S-3 registration statement to register up to 16,450,442 shares of commo
May 22, 2026
NEUTRAL
10-K/A
2/10
Serina Therapeutics, Inc. filed an amended 10-K/A solely to correct an incorrect version of the audi
Mar 27, 2026
Historical analyst distribution (last covering-analyst action Aug 2025): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$11.00 mean target (Aug 2025)
$11.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $1.84 |
| Target Low | $11.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $11.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.35 | $-0.35 | $-0.35 | 47.0% | +23.1% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next Q 2026-09-30 |
$-0.35 | $-0.35 | $-0.35 | 31.8% | +23.9% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.41 | $-1.41 | $-1.41 | — | +21.9% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-1.05 | $-1.05 | $-1.05 | 25.5% | +25.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.350 | |
| 7d ago | $-0.480 | +0.130 |
| 30d ago | $-0.455 | +0.105 |
| 60d ago | $-0.455 | +0.105 |
| 90d ago | $-0.455 | +0.105 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 14, 2025 | HC Wainwright & Co. | INITIATE | — | Buy |
| Mar 11, 2025 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 19, 2026
earnings_calendar
SER Q1 2026 Earnings Scheduled — 2026-05-19
May 14, 2026
earnings
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><i> Phase 1b </i><i>Registrational Clinical Study </i><i>of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD
Apr 7, 2026
other
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
<p align="justify">– <i>Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma </i></p>
Apr 2, 2026
other
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
<p align="justify"><strong>HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- </strong>Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE Ameri
Mar 31, 2026
short_volume
Short Volume: SER — 57.4% short (0.4M / 0.7M)
Short: 378,864 | Exempt: 47,816 | TRF Vol: 659,659 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
SER Q4 2025 Earnings After Market Close — 2026-03-30
Mar 25, 2026
fda
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
<p><b><i>-</i></b><b><i> FDA Grants IND Clearance for SER-252</i></b><br><b><i>- </i></b><b><i>SER-252 Phase 1b Trial Initiated</i></b><br><b><i>-</i>
Mar 24, 2026
other
Serina Therapeutics to Present at the 38th Annual Roth Conference
<p align="justify"><strong>HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- </strong>Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a
Mar 24, 2026
short_interest
FTD: SER — 448,300 shares ($1.4M) failed to deliver
Settlement: 20260324, Price: $3.15, FTD Value: $1,412,145, SERINA THERAPEUTICS INC COM (D
Mar 23, 2026
short_interest
FTD: SER — 1,394,248 shares ($3.5M) failed to deliver
Settlement: 20260323, Price: $2.54, FTD Value: $3,541,389.92, SERINA THERAPEUTICS INC COM (D
Mar 23, 2026
earnings_calendar
SER Q4 2026 Earnings Scheduled — 2026-03-23
Mar 20, 2026
short_interest
FTD: SER — 2,145,916 shares ($5.3M) failed to deliver
Settlement: 20260320, Price: $2.48, FTD Value: $5,321,871.68, SERINA THERAPEUTICS INC COM (D
Mar 18, 2026
offering
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
<p align="center">- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 mil